GlassScriptPhysician profile
Janet L Brock
NPI 1225287493
$599.18
in general payments reported to CMS, 2019-2025
10 companies · $72.15 in 2025
The $72.15 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $34.70 · 2023: $243 · 2024: $249 · 2025: $72.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $465 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $464.53 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $168.65 | 2022-2024 | |
| Exelixis INC. | $127.58 | 2023-2024 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $69.40 | 2024-2025 | |
| Celgene Corporation | $57.58 | 2023 | |
| Stemline Therapeutics INC. | $37.74 | 2024-2025 | Orserdu |
| Astrazeneca Pharmaceuticals LP | $37.63 | 2023-2024 | Imfinzi, Enhertu |
| Janssen Biotech, INC. | $34.23 | 2024 | Rybrevant |
| Array Biopharma INC | $27.09 | 2024 | Lorbrena, Mektovi, Braftovi |
| Pharmacosmos Therapeutics INC. | $25.33 | 2023 | Monoferric |
| Merck Sharp & Dohme LLC | $13.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Brock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.